Ken Griffin’s LAVA Therapeutics LVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-53,308
| Closed | -$83.2K | – | 13496 |
|
|
2025
Q3 | $83.2K | Buy |
53,308
+1,504
| +3% | +$2.25K | ﹤0.01% | 11951 |
|
|
2025
Q2 | $68.4K | Buy |
51,804
+46,781
| +931% | +$59.6K | ﹤0.01% | 11606 |
|
|
2025
Q1 | $6.38K | Buy |
+5,023
| New | +$5.59K | ﹤0.01% | 13762 |
|
|
2024
Q4 | – | Sell |
-17,013
| Closed | -$28.2K | – | 15026 |
|
|
2024
Q3 | $28.2K | Sell |
17,013
-49,224
| -74% | -$90.1K | ﹤0.01% | 12488 |
|
|
2024
Q2 | $119K | Buy |
+66,237
| New | +$175K | ﹤0.01% | 10661 |
|
|
2024
Q1 | – | Sell |
-21,552
| Closed | -$47.4K | – | 15115 |
|
|
2023
Q4 | $34.1K | Buy |
+21,552
| New | +$30.8K | ﹤0.01% | 12153 |
|
|
2023
Q2 | – | Sell |
-27,898
| Closed | -$46.3K | – | 14865 |
|
|
2023
Q1 | $46.3K | Buy |
+27,898
| New | +$78.1K | ﹤0.01% | 12254 |
|
|
2021
Q3 | – | Sell |
-61,874
| Closed | -$674K | – | 14308 |
|
|
2021
Q2 | $674K | Buy |
61,874
+1,432
| +2% | +$17.8K | ﹤0.01% | 9331 |
|
|
2021
Q1 | $918K | Buy |
+60,442
| New | +$830K | ﹤0.01% | 8335 |
|
Ken Griffin's LVTX Position: Q4 2025 in Review
Ken Griffin sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 53,308 shares — an estimated $83.2K sold.
Ken Griffin first reported a position in LVTX in Q1 2021 and held it in 9 quarters. The position peaked at $918K in Q1 2021. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.
- Ken Griffin reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
- Ken Griffin sold 53,308 LAVA Therapeutics shares in Q4 2025, an estimated $83.2K.
- Ken Griffin first reported a position in LAVA Therapeutics in Q1 2021 and held it in 9 quarters.
- Ken Griffin's LAVA Therapeutics position peaked at $918K in Q1 2021.
- 0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.